Clinical Trials Logo

Thromboembolism clinical trials

View clinical trials related to Thromboembolism.

Filter by:

NCT ID: NCT04969653 Active, not recruiting - Atopic Dermatitis Clinical Trials

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Start date: June 21, 2021
Study type: Observational

This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.

NCT ID: NCT04963374 Recruiting - Clinical trials for Venous Thromboembolism

the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients

Start date: April 1, 2021
Study type: Observational

To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism on the risk of concomitant VTE in respiratory inpatients to provide a basis for clinical VTE assessment and treatment.

NCT ID: NCT04947514 Not yet recruiting - Clinical trials for Venous Thromboembolism

Use of Tranexamic Acid in Reduction Mammoplasty

Start date: August 2021
Phase: Phase 4
Study type: Interventional

Breast reduction mammoplasty (BRM) is among the most commonly performed procedures in plastic surgery. However, postoperative hematoma is one of the most common complications following BRM. Hematoma-related complications include unplanned surgery, need for blood transfusion, wound healing issues, and unfavorable surgical outcomes. Tranexamic acid has emerged in the literature as a promising agent that reduces perioperative blood loss and need for transfusion. However, despite its consistently reported efficacy, low cost, and favorable safety profile, tranexamic acid remains underutilized in plastic surgery. We propose a prospective, double-blinded randomized controlled study of the efficacy of tranexamic acid in reducing hematoma development in patients undergoing reduction mammoplasty. We hope to contribute to the growing body of literature supporting tranexamic acid to reduce unwanted surgical bleeding.

NCT ID: NCT04940377 Completed - Clinical trials for Venous Thromboembolism

Effect of the Genotype on Postoperative DVT

Start date: June 1, 2020
Study type: Observational [Patient Registry]

Postoperative Venous Thromboembolism Events (VTE) constitute a major source of morbidity and mortality after surgery. The aim of this study was to investigate whether commonly occurring Single Nucleotide Polymorphisms (SNPs) are associated with VTE in the surgical setting.

NCT ID: NCT04923139 Not yet recruiting - Clinical trials for Treatment of Venous Thromboembolism

A Study to Learn About Venous Thromboembolism (VTE) Treatment With Rivaroxaban in Japanese Patients Using a Claims Database

Start date: August 15, 2021
Study type: Observational

This is an observational study in which data from the past is collected for a treatment which is already available for doctors to prescribe for venous thromboembolism (VTE). VTE is a condition in which blood clots form in veins, which can lead to disability and death. This study looks at the bleeding risk in Japanese patients who are already receiving long-term rivaroxaban treatment for their VTE. Some common causes of VTE are surgery, lack of movement, being bed-ridden and cancer. VTE that is caused by cancer is called cancer-associated venous thromboembolism (Ca-VTE). The study treatment, rivaroxaban, is a blood thinner prescribed by doctors to help treat conditions like VTE. By thinning the blood, rivaroxaban can help keep blood flowing normally and prevent blood clots. But, rivaroxaban can lead to increased bleeding in some people. There have been studies done in which participants with VTE and Ca-VTE received treatment with rivaroxaban for a long period of time. The overall results of those studies showed that long-term treatment with rivaroxaban helped prevent blood clots in those participants. Some of the participants had increased bleeding after this long-term treatment, while some did not. Participants with certain types of cancers, such as Ca-VTE, also had an increased risk of bleeding. These studies, however, did not include Japanese participants. So, the researchers in this study want to learn more about the risk of bleeding in Japanese patients with VTE or Ca-VTE who receive long-term treatment with rivaroxaban. To do this, the researchers plan to use a medical database to find information for patients with VTE and Ca-VTE who have already been taking rivaroxaban for their condition. This database will help the researchers collect information about the bleeding risk of long-term rivaroxaban treatment in Japanese patients. In this study, the researchers will learn more about: - the characteristics of patients with VTE who are treated with rivaroxaban for a period of less than 3 months to more than 1 year - the bleeding risk for all of the patients throughout the study - the bleeding risk for the patients with Ca-VTE throughout the study - the cause of any bleeding that happens The researchers will follow and record these results for Japanese patients from October 2015 to December 2020.

NCT ID: NCT04920487 Not yet recruiting - Clinical trials for Venous Thromboembolism

Prevalence of Gynecological Pathologies and Use of Hormonal Treatments in Women Hospitalized for a Venous Thromboembolic Episode

Start date: June 8, 2021
Study type: Observational

The incidence of venous thrombosis (venous thromboembolic disease: VTE) in women of childbearing age in France is in the order of 0.3 to 0.5 / 1000 women / year. It is a rare disease, but the majority of events occurring in women of childbearing age are associated with a particular hormonal context (mainly pregnancy and hormonal contraception). VTE is a multifactorial disease and the risk depends on the simultaneous presence of several triggers.

NCT ID: NCT04895553 Not yet recruiting - Glioma, Malignant Clinical Trials

Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

Start date: June 2021
Study type: Observational

Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will be enrolled into our study and will collect data regarding recurrent VTE and Intracranial hemorrhage and the incidence of these events.

NCT ID: NCT04883385 Recruiting - Clinical trials for Thromboembolic Disease

Thromboprophylaxis by Low Molecular Heparin During the Post-partum Period

Start date: June 4, 2021
Study type: Observational

The purpose of this study is to determine the current level of adequacy of the thromboprophylaxis prescriptions with the specific institutional protocol during the post-partum period. The institutional protocol is based on national and international guidelines.

NCT ID: NCT04865913 Recruiting - Covid19 Clinical Trials

Venous Thrombosis Virtual Surveillance in COVID

Start date: January 13, 2021
Study type: Observational

The overall goal of the VVIRTUOSO study is to determine the incidence of VTE including symptomatic DVT and PE after hospital discharge in patients with COVID-19 by implementing a pragmatic patient-centred prospective virtual VTE monitoring program in Canada and the United States.

NCT ID: NCT04861506 Recruiting - Safety Issues Clinical Trials

The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.

Start date: January 1, 2021
Study type: Observational

Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.